HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Protara Therapeutics (NASDAQ:TARA) and maintained a $23 price target.
August 08, 2024 | 11:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Protara Therapeutics and maintained a $23 price target.
The reiteration of a Buy rating and the maintenance of a $23 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100